ALVO vs. QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMD
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Alvotech vs. Its Competitors
Alvotech (NASDAQ:ALVO) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Qiagen has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alvotech had 5 more articles in the media than Qiagen. MarketBeat recorded 9 mentions for Alvotech and 4 mentions for Qiagen. Alvotech's average media sentiment score of 0.97 beat Qiagen's score of 0.33 indicating that Alvotech is being referred to more favorably in the media.
Alvotech currently has a consensus price target of $18.00, suggesting a potential upside of 99.56%. Qiagen has a consensus price target of $49.40, suggesting a potential upside of 4.02%. Given Alvotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alvotech is more favorable than Qiagen.
Alvotech has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Alvotech has a net margin of 16.42% compared to Qiagen's net margin of 4.68%. Qiagen's return on equity of 14.61% beat Alvotech's return on equity.
Summary
Qiagen beats Alvotech on 9 of the 16 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
This page (NASDAQ:ALVO) was last updated on 7/8/2025 by MarketBeat.com Staff
